Sail Biomedicines
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Sail Biomedicines - overview
Established
2023
Location
-, -, US
Primary Industry
Biotechnology
About
Based in the US and founded in 2023, Sail Biomedicines, a. k. a. Sail operates as a biotechnology company that leverages eRNA and nanoparticle deployment technology to design programmable medicines.
In October 2023, Senda Biosciences, Inc. , a portfolio company of Flagship Pioneering, Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Michigan Department of Treasury, and Partners Investment, Bluwave Capital LLC, Mint Venture Partners, Qatar Investment Authority, Stage 1 Ventures, and Samsung C&T Corporation, merged with Laronde Inc. to form Sail Biomedicines. As of October 2023, Guillaume Pfefer is the CEO of the company.
Sail Biomedicines is building data, enabling the use of generative AI techniques to identify and design fully programmable medicines. The company’s platform combines programmable circular RNA technology (Endless RNA™ or eRNA), and a platform of programmable nanoparticles, utilizing natural components, to unlock the comprehensive programming of medicines.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.